Regorafenib monohydrate is a potent multikinase inhibitor primarily utilized in the treatment of metastatic colorectal cancer and advanced gastrointestinal stromal tumors. By acting as a dual inhibitor… Read more
Regorafenib monohydrate is a potent multikinase inhibitor primarily utilized in the treatment of metastatic colorectal cancer and advanced gastrointestinal stromal tumors. By acting as a dual inhibitor of VEGFR2 and TIE2 tyrosine kinases, this compound effectively suppresses tumor angiogenesis. Laboratories rely on high-quality reference standards of Regorafenib monohydrate, along with its pharmacopeial and non-pharmacopeial impurities, to perform rigorous analytical testing and quality control. These materials are essential for accurate impurity profiling and method validation, ensuring compliance with regulatory requirements throughout drug development. Furthermore, stable isotope-labelled versions of the drug serve as critical internal standards for mass spectrometry-based bioanalytical assays. Providing access to these specialized compounds allows analytical scientists to maintain the precision and reproducibility necessary for evaluating pharmaceutical substances and monitoring degradation products within complex matrices.